News Releases

Relmada Therapeutics Selected to Present at 2016 Biotech Showcase™ in San Francisco
Presentation on January 13, 2016 at 2:00 PM Pacific Time.

NEW YORK, Jan. 11, 2016 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD) a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that the company has been selected to present at the 8th Annual Biotech Showcase™ Conference at 2:00 PM Pacific Time (5:00 PM Eastern Time) on Wednesday, January 13, 2016. The presentation will take place in Track C – Mission II at the Parc 55 Hotel in San Francisco.

Relmada Therapeutics Corporate Logo

Sergio Traversa, Chief Executive Officer of Relmada Therapeutics, will provide an overview of the Company and recent activities, including the recent topline results of a proof-of-concept pharmacokinetic study in healthy volunteers using BuTab (REL-1028), an investigational, oral formulation of buprenorphine, an opioid that is broadly used to treat both addiction and chronic pain.

A live audio webcast of the presentation will be available under the Investor Relations section of Relmada's website at www.relmada.com. A replay of the presentation will be available for 30 days following the event. Please connect to Relmada's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The Company has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit Relmada's website at: www.relmada.com.

Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. We may from time to time make written or oral statements in this letter, the proxy statements filed with the SEC communications to stockholders and press releases which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based upon management's current expectations, estimates, assumptions and beliefs concerning future events and conditions and may discuss, among other things, anticipated future performance, expected product development, product potential, future business plans and costs. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to" and similar expressions. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all of the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be considered to be a complete list.

Contacts
Investors:
Michael Becker, SVP of Finance and Corporate Development
Relmada Therapeutics Inc.
Tel: 212-376-5776
mbecker@relmada.com

Logo - http://photos.prnewswire.com/prnh/20150113/168770LOGO

SOURCE Relmada Therapeutics, Inc.